Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
About Xenetic Biosciences Inc.
Xenetic Biosciences Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company dedicated to advancing innovative immuno-oncology technologies and next-generation biologic therapeutics. With a focus on addressing hard-to-treat cancers and other severe medical conditions, Xenetic leverages its proprietary platforms to develop transformative therapies that improve patient outcomes.
Core Technologies
The company's flagship technology, the DNase-based oncology platform, is designed to target neutrophil extracellular traps (NETs), which are implicated in cancer progression, metastasis, and resistance to existing therapies. By reducing NETs burden in the tumor microenvironment, Xenetic's DNase platform enhances the efficacy of immunotherapies, adoptive cell therapies, and chemotherapies. This technology is being developed as an adjunctive treatment for pancreatic carcinoma, colorectal cancer, and other locally advanced or metastatic solid tumors.
Another key innovation is the PolyXen™ platform, which improves the pharmacological properties of biologic drugs, including extended half-life and reduced immunogenicity. This platform is being utilized in collaborations with global pharmaceutical companies to develop next-generation biologics, such as polysialylated blood coagulation factors.
Pipeline and Partnerships
Xenetic's pipeline includes investigational therapies targeting significant unmet needs in oncology. The company is advancing its systemic DNase program into clinical trials, focusing on its potential as an adjunctive therapy in combination with chemotherapy and immune checkpoint inhibitors. Preclinical studies have demonstrated encouraging results, including enhanced tumor suppression, improved T-cell activation, and prolonged survival in animal models.
Collaborations play a pivotal role in Xenetic's strategy. The company has established partnerships with institutions such as the University of Virginia and PeriNess Ltd., leveraging their expertise to accelerate preclinical and clinical development. Additionally, Xenetic's sublicense agreement with Takeda Pharmaceuticals for the PolyXen platform generates royalty revenues, supporting its broader research and development efforts.
Market Position and Competitive Edge
Operating within the highly competitive oncology sector, Xenetic differentiates itself through its focus on NET-targeting therapies and its ability to enhance existing treatment paradigms. By addressing the immunosuppressive tumor microenvironment and improving the efficacy of established therapies, the DNase platform holds the potential to transform treatment outcomes for patients with aggressive and resistant cancers.
The company's emphasis on collaboration, coupled with its proprietary technologies, positions it as a key innovator in the field of immune-oncology. Its strategic focus on hard-to-treat cancers underscores its commitment to addressing significant unmet medical needs.
Conclusion
With a robust pipeline, cutting-edge technologies, and strategic partnerships, Xenetic Biosciences Inc. is at the forefront of developing novel therapies that aim to redefine cancer treatment. By targeting critical mechanisms like NETs and leveraging its expertise in biologics, the company continues to make strides toward delivering impactful solutions for patients and healthcare providers.
Xenetic Biosciences (NASDAQ: XBIO) has announced a significant collaboration with The Scripps Research Institute to advance its systemic DNase-based oncology program, aimed at treating pancreatic carcinoma and other solid tumors. This partnership will enhance the development of the DNase platform, which targets neutrophil extracellular traps (NETs), implicated in cancer progression and therapeutic resistance. Xenetic plans to initiate a first-in-human study assessing the DNase in combination with immune checkpoint inhibitors or chemotherapy. Furthermore, the agreement allows Xenetic to acquire an exclusive license for any new intellectual property resulting from the research. This collaboration is seen as a critical step towards creating much-needed therapies for challenging cancer indications.
Xenetic Biosciences (NASDAQ: XBIO) reported significant developments in its annual results for 2022. The company is focusing on the DNase oncology platform, which targets neutrophil extracellular traps to improve cancer therapies. The DNase program is progressing towards Phase 1 clinical development and aims to provide treatments for pancreatic carcinoma and other solid tumors. The year ended with approximately $13.1 million in cash. Financially, the net loss for 2022 was $6.6 million, with a 50.8% increase in research and development expenses. A royalty payment of $1.7 million was received from a sublicense with Takeda, marking a 47.1% year-over-year increase.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced participation in the Virtual Investor NETs in Cancer Spotlight Event on March 29, 2023, at 11:00 AM ET. CEO Jeffrey Eisenberg, CSO Curtis Lockshin, and oncology leader Dr. Jonathan Spicer will discuss the Company's DNase-based oncology platform and the role of Neutrophil Extracellular Traps (NETs) in cancer. The event will feature a moderated roundtable discussion, enabling investors to submit questions live. A live video webcast will be available on Xenetic's website and archived for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,001,543, titled Method to Improve Safety and Efficacy of Anti-Cancer Therapy. This patent application aims to improve treatments for cancer patients by using a DNase enzyme to mitigate chemotherapy-associated side effects. CEO Jeffrey Eisenberg emphasized the company's commitment to advancing its DNase platform and strengthening its intellectual property portfolio. The approved patent enhances Xenetic's capabilities in the oncology sector, specifically targeting pancreatic carcinoma and other difficult-to-treat cancers.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
What does Xenetic Biosciences specialize in?
What is the DNase-based oncology platform?
What are Xenetic's key collaborations?
How does the PolyXen™ platform work?
What types of cancers is Xenetic targeting?
What differentiates Xenetic Biosciences from competitors?
Does Xenetic generate revenue?
What stage is Xenetic's DNase program in?
